
Curis (CRIS) Stock Forecast & Price Target
Curis (CRIS) Analyst Ratings
Bulls say
Curis Inc is positioned for positive growth with the anticipated launch of emavusertib, forecasted to generate revenues of $76.3 million in 2028 for acute myeloid leukemia (AML) and $15.6 million for non-Hodgkin’s lymphoma (NHL) that same year, with substantial growth expected through 2029. The company has demonstrated improved financial performance with third-quarter 2024 revenues slightly exceeding estimates and an upward revision of the 2024 EPS forecast, indicating better-than-expected operational efficiency. Furthermore, recent clinical trial data for emavusertib—showing promising results in patients with relapsed or refractory primary CNS lymphoma—highlights its potential efficacy, bolstering confidence in Curis's therapeutic pipeline.
Bears say
Curis Inc. appears to face significant challenges in its financial outlook, primarily due to its limited product pipeline and ongoing development expenses that may outweigh potential revenue opportunities from its oncology therapies. The company has reported consecutive losses, contributing to a concerning cash flow situation that raises questions about its ability to sustain operations without additional funding or successful commercialization of its drugs. Furthermore, competitive pressures in the biotechnology sector and regulatory hurdles for its treatments could further hinder Curis's growth prospects, leading to a pessimistic view on its future financial performance.
This aggregate rating is based on analysts' research of Curis and is not a guaranteed prediction by Public.com or investment advice.
Curis (CRIS) Analyst Forecast & Price Prediction
Start investing in Curis (CRIS)
Order type
Buy in
Order amount
Est. shares
0 shares